Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nordihydroguaiartic derivatives for use in treatment of tumors

a technology of nordihydroguaiaretic acid and derivatives, which is applied in the field of nordihydroguaiaretic acid derivatives, can solve the problems of laborious and costly separation and purification of plant lignans, and sub>4/sub>n certainly limits its use to the lowest effective concentration

Inactive Publication Date: 2005-12-01
THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
View PDF11 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a new compound called nordihydroguaiaretic acid derivative (M4N) that can inhibit the growth of tumors in animals, particularly humans. The compound has been found to specifically target the cyclin-dependent kinase CDC2 cycle, which is involved in cell proliferation. The patent also describes a method for treating cancerous and non-cancerous tumors by administering the compound to the tumor site. The compound can be administered through local injection or other means of local administration, such as topical application or targeted delivery to the tumor site. The amount of compound administered will vary depending on the desired treatment effect, but can be determined by those skilled in the art. The patent provides a valuable tool for treating cancer and other tumors in humans and other mammals.

Problems solved by technology

Isolation and purification of plant lignans, however, is labor intensive and costly.
Even so, the relatively low selective index of M4N certainly limits its use to the lowest effective concentration if the drug must be used systemically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nordihydroguaiartic derivatives for use in treatment of tumors
  • Nordihydroguaiartic derivatives for use in treatment of tumors
  • Nordihydroguaiartic derivatives for use in treatment of tumors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of M4N and several other NDGA derivatives of SP1-regulated HPV E6 / E7 promoter activity.

[0058] The effect of M4N and several other NDGA derivatives of SP1-regulated HPV E6 / E7 promoter activity was examined using luciferase as a reporter. The assay depends upon DNA transfection of the HPV16 LCR (P97 promoter) fused to the luciferase reporter gene into C33A cells by calcium phosphate methods. C33A is a cervical tumor cell line (ATCC accession no. HTB-31) that does not contain any integrated HPV DNA, but has transcription factors necessary for a robust expression of the HPV early gene promoter. One day following DNA transfection various drug concentrations dissolved with the help of dimethyl sulfoxide (DMSO) were added to the cells. Thirty hours after drug treatment (so that the assay is complete within the standard forty-eight hours for transient transfection experiments), the cells were lysed and specific luciferase activity was determined (Luciferase Assay Systems, Promega, ...

example 2

Inhibition of E6 / E7 mRNA Synthesis Following M4N Treatment

[0060] Inhibition of E6 / E7 mRNA synthesis following M4N treatment was measured by RT-PCR in cervical cell line C3. Relative RT-PCR was performed with quantities of total cellular RNA standardized to the cell numbers counted. The RT-PCR product was analyzed on a 2% agarose gel. The results are shown in FIG. 3. The RT-PCR results indicated that the amplified cDNAs of the expected size for E7 (321 bp) and E6 (204 bp) were detected in the DMSO treated cells as early as cycle 22 of amplification. These same products were barely detectable in the drug treated RNA extracts following 30 cycles of amplification. No amplified products were detected for the no template PCR control or from total RNA extracts of the HPV16-negative C33a cell line.

example 3

Inhibition of Cervical C3 Cell Growth by M4N Treatment

[0061] HPV-16 transformed immortal mouse epithelial cells (C3 cells) were plated at a density of 105 cells per vial. After 24 hours, ½ of the vials were given growth media containing 40 μMM4N dissolved in 1% DMSO while the other half were given growth media containing only 1% DMSO. The results are shown in FIG. 4A. Within 24 hrs a difference in cell morphology between drug treated and control C3 cells was observed. The growth and division of the drug treated cells was markedly reduced in comparison to the untreated control, while the fraction of viable cells compared to the total cell count remained constant for both drug treated and DMSO only control cells. This indicates that M4N dramatically reduces cell division.

[0062] The effect on C3 growth following removal of M4N from the medium was also examined. C3 cells were plated at a density of 104 cells per vial. At time=0, ⅔ of the vials were given growth media supplemented wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.

Description

[0001] This application claims priority to U.S. application Ser. No. 09 / 418,594, filed Oct. 15, 1999, which is hereby incorporated by reference.[0002] The invention described and claimed herein was made in part under a grant from the National Institutes of Health. The U.S. Government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] 1. Field of the Invention [0004] The invention relates to the use of nordihydroguaiaretic acid derivatives, in particular derivatives containing substituents of naturally occurring amino acids, for the treatment of tumors and viral infections. [0005] 2. Background Information [0006] Carcinogenesis is a multistage event affected by a variety of genetic and epigenetic factors and is typified by the outbreak of uncontrolled cell growth originated from different tissues. A universal goal for anticancer research lies in the development of a clinical treatment that is highly effective in curtailment of tumor growth, non-toxic to the host, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/20A61K31/05A61K31/09A61K31/198A61K31/22A61K31/223A61K31/225A61K31/401A61K31/405A61K31/417A61P35/00A61P35/04A61P43/00C07C229/12
CPCA61K9/0014A61K9/0019A61K31/05A61K31/198A61K31/417A61K31/225A61K31/401A61K31/405A61K31/22A61P31/18A61P35/00A61P35/04A61P43/00
Inventor HUANG, RU CHIH C.HELLER, JONATHAN D.HWU, JIH RUKING, KO YUNG
Owner THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com